GENELUX CORPORATION
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2001-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.genelux.com
Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
- Conditions
- Advanced Non-squamous Non-small-cell Lung CancerAdvanced Squamous Non-Small Cell Lung CarcinomaNon-small Cell Lung Cancer RecurrentMetastatic Non-squamous Non Small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung CarcinomaNon-small Cell Lung CancerNon-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer Stage III
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- Genelux Corporation
- Target Recruit Count
- 142
- Registration Number
- NCT06463665
- Locations
- 🇺🇸
Oncology & Hematology Associates of West Broward, Coral Springs, Florida, United States
🇺🇸Sheboygan Cancer & Blood Center, Sheboygan, Wisconsin, United States
🇺🇸Pioneer Research Center, LLC, Bullhead City, Arizona, United States
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Conditions
- Platinum-resistant Ovarian CancerPlatinum-refractory Ovarian CancerPrimary Peritoneal CancerFallopian Tube CancerEndometrioid Ovarian CancerHigh-grade Serous Ovarian CancerOvarian Clear Cell Carcinoma
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Genelux Corporation
- Target Recruit Count
- 186
- Registration Number
- NCT05281471
- Locations
- 🇺🇸
The University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care
- Conditions
- Advanced Stage Cancer (Solid Tumor Disease for 4 Patients)Acute Myeloid Leukemia (6 Patients)
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Genelux Corporation
- Registration Number
- NCT03420430
- Locations
- 🇺🇸
Florida Hospital Cancer Institute, Orlando, Florida, United States
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
- Conditions
- Peritoneal CarcinomatosisFallopian Tube CancerOvarian Cancer
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Genelux Corporation
- Target Recruit Count
- 46
- Registration Number
- NCT02759588
- Locations
- 🇺🇸
Gynecologic Oncology Associates, Newport Beach, California, United States
🇺🇸AdventHealth Cancer Institute, Orlando, Florida, United States
Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer
- Conditions
- Cancer of Head and Neck
- First Posted Date
- 2012-04-24
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Genelux Corporation
- Target Recruit Count
- 19
- Registration Number
- NCT01584284
- Locations
- 🇺🇸
Moores UC San Diego Cancer Center, La Jolla, California, United States
News
Oncolytic Virus Cancer Therapy Pipeline Shows Strong Growth with 120+ Companies Developing 125+ Treatments
The oncolytic virus cancer therapy market is experiencing robust growth with over 120 companies actively developing 125+ pipeline therapies, representing a significant expansion in this therapeutic segment.
FDA Signals Potential Traditional Approval Pathway for Genelux's Olvi-Vec in Platinum-Resistant Ovarian Cancer
FDA indicates that Genelux's ongoing Phase 3 OnPrime/GOG-3076 trial could potentially support traditional approval for Olvi-Vec in platinum-resistant/refractory ovarian cancer without requiring a separate confirmatory study.